PASITHEA THERAPEUTICS CORP. Financial Instrument Subject to Mandatory Redemption, Par Value Per Share
PASITHEA THERAPEUTICS CORP. (KTTA) had Financial Instrument Subject to Mandatory Redemption, Par Value Per Share of $1.01 per share as of 2022-06-21, per its 10-Q filed 2022-11-14.
Discontinued › Notes › Other Liabilities
us-gaap:FinancialInstrumentSubjectToMandatoryRedemptionParValuePerShare · last filed 2022-11-14
- 2022-06-21: Financial Instrument Subject to Mandatory Redemption, Par Value Per Share $1.01.
| Period end | Financial Instrument Subject to Mandatory Redemption, Par Value Per Share |
|---|---|
| 2022-06-21 | $1.01 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Rocket One Inc. (RKTO) | United States | $0.019B |